ADVM Stock Overview
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases.
Adverum Biotechnologies Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$1.18|
|52 Week High||US$3.66|
|52 Week Low||US$0.80|
|1 Month Change||28.04%|
|3 Month Change||-9.23%|
|1 Year Change||-66.76%|
|3 Year Change||-90.30%|
|5 Year Change||-53.73%|
|Change since IPO||-95.31%|
Recent News & Updates
|ADVM||US Biotechs||US Market|
Return vs Industry: ADVM underperformed the US Biotechs industry which returned -25.1% over the past year.
Return vs Market: ADVM underperformed the US Market which returned -21.2% over the past year.
|ADVM Average Weekly Movement||8.8%|
|Biotechs Industry Average Movement||13.2%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.8%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: ADVM is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: ADVM's weekly volatility (9%) has been stable over the past year.
About the Company
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek.
Adverum Biotechnologies Fundamentals Summary
|ADVM fundamental statistics|
Is ADVM overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ADVM income statement (TTM)|
|Cost of Revenue||US$88.78m|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.57|
|Net Profit Margin||0.00%|
How did ADVM perform over the long term?See historical performance and comparison
Is ADVM undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for ADVM?
Other financial metrics that can be useful for relative valuation.
|What is ADVM's n/a Ratio?|
Price to Book Ratio vs Peers
How does ADVM's PB Ratio compare to its peers?
|ADVM PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
FIXX Homology Medicines
LPTX Leap Therapeutics
DTIL Precision BioSciences
ADVM Adverum Biotechnologies
Price-To-Book vs Peers: ADVM is good value based on its Price-To-Book Ratio (0.4x) compared to the peer average (1.5x).
Price to Earnings Ratio vs Industry
How does ADVM's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: ADVM is good value based on its Price-To-Book Ratio (0.4x) compared to the US Biotechs industry average (1.5x)
Price to Book Ratio vs Fair Ratio
What is ADVM's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||0.4x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate ADVM's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of ADVM when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate ADVM's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate ADVM's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ADVM's PEG Ratio to determine if it is good value.
Discover undervalued companies
How is Adverum Biotechnologies forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ADVM is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ADVM is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ADVM is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ADVM is forecast to have no revenue next year.
High Growth Revenue: ADVM is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if ADVM's Return on Equity is forecast to be high in 3 years time
Discover growth companies
How has Adverum Biotechnologies performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ADVM is currently unprofitable.
Growing Profit Margin: ADVM is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ADVM is unprofitable, and losses have increased over the past 5 years at a rate of 18.3% per year.
Accelerating Growth: Unable to compare ADVM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ADVM is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (98.2%).
Return on Equity
High ROE: ADVM has a negative Return on Equity (-54.78%), as it is currently unprofitable.
Discover strong past performing companies
How is Adverum Biotechnologies's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: ADVM's short term assets ($280.1M) exceed its short term liabilities ($23.2M).
Long Term Liabilities: ADVM's short term assets ($280.1M) exceed its long term liabilities ($101.2M).
Debt to Equity History and Analysis
Debt Level: ADVM is debt free.
Reducing Debt: ADVM has no debt compared to 5 years ago when its debt to equity ratio was 0.04%.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ADVM has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ADVM has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 21.7% each year.
Discover healthy companies
What is Adverum Biotechnologies's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ADVM's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ADVM's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ADVM's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ADVM's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as ADVM has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Laurent Fischer (58 yo)
Dr. Laurent Fischer, M.D., served as a Senior Advisor of Frazier Management, L.L.C. since March 2017 till May 2022. He joined the firm in March 2017. He was on the Frazier Life Sciences team and has severa...
CEO Compensation Analysis
Compensation vs Market: Laurent's total compensation ($USD9.00M) is above average for companies of similar size in the US market ($USD800.58K).
Compensation vs Earnings: Laurent's compensation has been consistent with company performance over the past year.
Experienced Management: ADVM's management team is not considered experienced ( 1 years average tenure), which suggests a new team.
Experienced Board: ADVM's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ADVM insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Adverum Biotechnologies, Inc.'s employee growth, exchange listings and data sources
- Name: Adverum Biotechnologies, Inc.
- Ticker: ADVM
- Exchange: NasdaqGM
- Founded: 2006
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$116.549m
- Shares outstanding: 98.77m
- Website: https://www.adverum.com
Number of Employees
- Adverum Biotechnologies, Inc.
- 800 Saginaw Drive
- Redwood City
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/07/03 00:00|
|End of Day Share Price||2022/07/01 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.